Quantcast

Latest ClinicalTrials.gov Stories

2011-12-28 08:05:42

Despite the importance of site investigators to the success of multicentre clinical trials, inadequate public information is available about their recruitment performance. In this week's PLoS Medicine, Rafael Dal-Ré and colleagues argue that that sponsors should disclose the recruitment targets of all site investigators on ClinicalTrials.gov before a trial starts, as well as their final recruitment. Information on issues that could have affected recruitment should also be...

2011-06-27 07:30:00

ROCKVILLE, Md., June 27, 2011 /PRNewswire/ -- Glycotex, Inc., a clinical stage biopharmaceutical company, announced today that it has submitted the final results of the two completed Phase II clinical studies of its drug product candidate, GLYC-101 gel, to the clinicaltrials.gov database. These clinical studies have evaluated the effect of investigational GLYC-101 on wound closure in patients undergoing carbon dioxide laser skin resurfacing. The pilot randomized, double-blind,...

2011-05-03 08:00:00

ANN ARBOR, Mich., May 3, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that after scientific review, the ongoing clinical trial of its Trimesta(TM) (oral estriol) drug candidate for multiple sclerosis (MS) has received an additional $1,594,553 in grant funding from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS). The clinical...

2011-02-04 01:30:00

WAYNE, N.J., Feb. 4, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA). Regorafenib is an investigational agent and is not approved by the FDA, the European Medicines Agency (EMA) or other Health Authorities. "This is an important step in the overall...

2010-12-06 06:00:00

Company to discuss interim results from Phase I/II trial of CYT387 being presented today at the 52(nd) American Society of Hematology Annual Meeting ORLANDO, Dec. 6 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM) announced that it will hold an analyst meeting and conference call today at 12:30pm ET to discuss the interim results from the first 60 patients enrolled in the 140 patient Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, in myelofibrosis. An oral...

2010-11-18 07:27:00

MISSISSAUGA, ON, Nov. 18 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients. YM also announced that the trial protocol has been extended to allow...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related